Proton Therapy Research Infrastructure- ProTRAIT- Neuro-oncology

Launched by MAASTRICHT RADIATION ONCOLOGY · Nov 23, 2020

Keywords

ClinConnect Summary

The ProTRAIT clinical trial is studying the use of proton therapy for treating certain types of brain tumors, including astrocytomas and ependymomas. Proton therapy is a special kind of radiation treatment that can target tumors more precisely, which helps spare healthy tissues and reduces the risk of side effects compared to traditional radiation (photon therapy). This trial aims to evaluate how effective proton therapy is in lessening complications from treatment and improving patients’ outcomes.

To be eligible for this trial, participants must be at least 18 years old and have a brain tumor that has a good prognosis, meaning they are expected to survive for more than ten years. They should also have minimal cognitive impairment and be in good overall health. Those who join the trial can expect to undergo assessments that compare proton therapy with traditional methods to see which is better for their specific situation. The trial is currently recruiting participants across the Netherlands, and the data collected will help improve treatment options for future patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. All brain tumors with a favorable prognosis (median survival \> 10 year)
• • 2. Age ≥ 18 years
• • 3. ECOG performance status 0 - 1 / Karnofsky performance status 80 - 100
• • 4. No - minimal neurocognitive impairment
• • 5. Dosimetrical gain of protontherapy relative to photontherapy (≥5% on supratentorial brain dose or hippocampi)
• • 6. Informed consent
• Exclusion Criteria:
• • 1. Not eligible for chemotherapy
• • 2. Eligible for stereotactic radiotherapy